Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Core Insights - Globus Medical, Inc. reported strong financial results for Q4 and the full year of 2025, with double-digit sales and earnings growth, driven by the successful integration of recent acquisitions and a focus on innovation [4][5]. Financial Performance - Q4 2025 worldwide net sales reached $826.4 million, a 25.7% increase from Q4 2024, with U.S. net sales up 27.5% and international sales up 19.0% [4][5]. - For the full year 2025, worldwide net sales totaled $2,938.9 million, reflecting a 16.7% increase over 2024, with U.S. sales increasing by 18.4% and international sales by 10.0% [5][6]. - GAAP net income for Q4 2025 was $140.6 million, a significant increase of 430.4% year-over-year, primarily due to higher sales and contributions from the Nevro acquisition [6][7]. - Non-GAAP diluted EPS for Q4 2025 was $1.28, up 52.1% from $0.84 in Q4 2024 [7][8]. Business Segments - The U.S. Spine business grew revenue by 10% in Q4 2025 compared to the prior year, while Enabling Technologies saw a remarkable growth of 19% [4][6]. - For the full year, Musculoskeletal Solutions generated $2,797.9 million in sales, while Enabling Technologies contributed $141.0 million [31]. Guidance and Future Outlook - The company reaffirmed its 2026 revenue guidance in the range of $3.18 to $3.22 billion and updated its non-GAAP fully diluted EPS guidance to $4.40 to $4.50 [9]. - The focus for 2026 includes scaling growth, expanding the sales force, and launching a robust new product pipeline to address unmet clinical needs [4][9]. Cash and Liquidity - As of December 31, 2025, cash and cash equivalents were $526.2 million, down from $784.4 million in 2024, with total cash, cash equivalents, and marketable securities at $629.1 million [33]. - The company generated $753.4 million in net cash from operating activities for the year, a significant increase from $520.6 million in 2024 [28]. Integration and Strategic Initiatives - The successful integration of NuVasive and Nevro has been highlighted as a key driver of value creation and market penetration [4][6]. - The company aims to enhance surgical outcomes through its Globus surgical intelligence closed-loop ecosystem, which integrates patient selection, surgical techniques, and complementary implants [4].